Hyperfine, Inc. (HYPR) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reflect a positive outlook. Despite a slight net loss, the company shows strong financial discipline with reduced expenses and cash burn. Revenue guidance indicates significant growth, supported by new product launches and international expansion. The Q&A session highlights management's confidence in revenue drivers and market opportunities. While some responses lacked specificity, the overall sentiment is positive due to improved financial metrics, promising guidance, and strategic growth initiatives.
Key Financial Performance
Revenue $2.7 million, up 26% sequentially. The increase was driven by the sale of 8 systems, including the first next-generation Swoop system in a hospital before quarter end. A second hospital deal closed on July 1, which would have increased revenue to over $3 million if it had closed earlier.
Gross Margin 49.3%, representing an 800 basis point increase sequentially. This improvement was due to the increased number of units sold and a higher average selling price.
R&D Expenses $4.5 million, a sequential decrease from $5 million in Q1 2025. The reduction reflects benefits from a reorganization completed in Q1 as the company transitions to a commercial growth stage.
Sales, General, and Administrative Expenses $6.4 million, a sequential decrease from $6.7 million in Q1 2025. This reduction is attributed to spending discipline and optimization of operating leverage.
Net Loss $9.2 million, equating to a net loss of $0.12 per share, compared to a net loss of $9.4 million or $0.12 per share in the prior quarter. The slight improvement is due to reduced expenses.
Net Cash Burn (Excluding Financing) $8.1 million, down 19% sequentially from the prior quarter. This reduction highlights the company's focus on spending discipline and optimizing operating leverage.
Cash and Cash Equivalents $25.4 million as of June 30, 2025. This reflects the company's financial position at the end of the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-generation Swoop system: Launched with transformative image quality, powered by Optive AI software. First commercial sale achieved within 30 days of FDA clearance. Designed for broad adoption across multiple care sites, including emergency rooms and neurology clinics. MSRP set at $550,000, a 15% premium over the prior version.
Optive AI software: Cleared as standalone software and integrated into the next-generation Swoop system. Enhances image quality and reduces scan time. Recognized as a leader in AI-powered image quality by Healthy Imaging and FDA.
U.S. market expansion: Revenue diversified across hospitals, office settings, and international markets. Neurology offices targeted as a new market with significant potential. Partnering with NeuroNet to promote adoption in neurology practices.
International market expansion: Optive AI software launched in Canada, Australia, and New Zealand. European launch expected by end of 2025, and regulatory approval in India anticipated by end of 2025. Next-generation Swoop system to be available internationally by end of 2026.
Revenue growth: Achieved $2.7 million in Q2 2025, up 26% sequentially. Expected 10%-20% revenue growth for full year 2025.
Gross margin improvement: Expanded gross margins by 800 basis points sequentially to 49%. Anticipated gross margin for 2025 is 47%-50%.
Cash burn reduction: Reduced cash burn by 19% sequentially in Q2 2025. Full-year cash burn expected to decline by 27% year-over-year.
Strategic focus on AI and innovation: AI integrated into portable MRI technology for enhanced image quality and usability. Recognized as a leader in AI-powered imaging by FDA and Healthy Imaging.
Diversified revenue streams: Selling into hospitals, offices, and international markets to ensure growth and scalability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company faces risks related to obtaining and maintaining regulatory approvals in international markets, such as Europe and India, which are expected by the end of 2025. Delays or failures in these approvals could impact international expansion plans.
Financial Performance: Despite revenue growth, the company reported a net loss of $9.2 million for Q2 2025. Cash burn remains a concern, with a total cash burn of $27-$29 million expected for the full year, potentially impacting long-term financial sustainability.
Market Adoption: The success of the next-generation Swoop system and Optive AI software depends on market adoption across hospitals, offices, and international markets. Failure to achieve widespread adoption could hinder revenue growth.
Competitive Pressures: The company operates in a competitive market for AI-powered medical imaging. Competitors with more established products or greater resources could challenge Hyperfine's market position.
Supply Chain and Manufacturing: Scaling manufacturing and building inventory for new product launches pose operational risks. Any disruptions in the supply chain could delay product availability and impact revenue.
Economic Uncertainties: Economic conditions, including healthcare budget constraints and reimbursement challenges, could affect purchasing decisions by hospitals and neurology offices.
Strategic Execution: The company is undergoing multiple simultaneous product launches and market expansions. Execution risks include delays in product rollouts, ineffective sales strategies, or misallocation of resources.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For the full year 2025, Hyperfine expects revenue growth to be in the range of 10% to 20% over 2024. This includes a significant revenue step-up in the second half of 2025, driven by multiple growth drivers such as the launch of the next-generation Swoop system, entry into the office setting, hospital site expansion, updated health economic selling, and international commercial traction.
Sequential Revenue Growth: Revenue is expected to show a sequential step-up in Q3 2025, with a more significant sequential increase in Q4 2025 and beyond. The Q3 sequential step-up is anticipated to be 50% greater than the revenue improvement from Q1 to Q2 2025.
Gross Margin: Gross margin for 2025 is expected to be in the range of 47% to 50%, representing a 280 basis point increase year-over-year at the midpoint. The company anticipates surpassing 50% gross margins sustainably as higher volumes are realized.
Cash Burn: Total cash burn for 2025 is projected to be in the range of $27 million to $29 million, representing a 27% decline year-over-year at the midpoint. The company expects a cash runway through the end of 2026.
Product Launches and Market Expansion: The next-generation Swoop system and Optive AI software are expected to drive growth in the second half of 2025. The company is focusing on U.S. hospitals, office settings, and international markets, with plans to launch in Europe and India by the end of 2025. The next-generation Swoop system is expected to be available in international markets by the end of 2026.
Market Opportunity: The total market opportunity for the Swoop system is estimated to exceed $6 billion, with the technology positioned as a first mover in portable AI-powered MRI systems.
Clinical Studies and Adoption: The PRIME study at Yale School of Medicine and the Neuro PMR study in neurology offices are expected to support the adoption of the Swoop system. Findings from the Neuro PMR study are anticipated in early 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on what gets you to the low end versus the high end of the 2025 revenue guidance range and the sequential growth in Q3 and Q4?
A:Management explained that the second half of the year will see a higher revenue base due to multiple launches. For Q3, they expect a 50% increase over the revenue increase posted between Q1 and Q2, which was $560,000. They are confident due to incremental revenue contributors such as U.S. hospital business acceleration, full launch phase in the U.S. office business, international market expansion, and improved product traction.
Q:What are your expectations for the Next-gen Swoop launch in the second half, including upgrade cycles, trade-ins, and new system placements?
A:Management stated that all components, including higher ASP, new placements, and modest revenue from upgrades, are positive for revenue trajectory. They are primarily focused on new system sales across hospitals and different sites of care. They also mentioned pipeline deals with hospitals and offices, emphasizing the traction of Optive AI in both first-generation and new systems.
Q:Can you elaborate on the traction in the office side of care and share metrics on placements, deals, or utilization?
A:Management shared that they are in the pilot phase with a handful of sites to ensure proper implementation, training, and economic viability. They emphasized the importance of scan volume, payer mix, and reimbursement rates for office economics. They also highlighted the success of the NeuroNet hub and the rapid enrollment in a 100-patient study, which exceeded expectations.
Q:Can you quantify the funnel interest to support the second half guidance of doubling system placements?
A:Management explained that they are managing separate funnels for hospital and office opportunities. Hospitals have a structured process, while office deals can vary in decision-making speed. They are also focusing on deeper market penetration in select international markets. The team has matured, and sales capabilities have improved, positioning them well for the second half.
Q:Which opportunity (office setting, OUS, next-gen Swoop system) will be the primary driver of second-half growth?
A:Management stated that the primary driver is showcasing the technology's capabilities and expanding use cases. They aim to balance accessibility and value without compromising on price or exclusivity. They highlighted the improved image quality and broader applications of Optive AI and the new scanner.
Q:What contributed to the increase in ASP this quarter, and will the new hardware affect international business timelines?
A:The ASP increase was due to a favorable mix, MSRP increases in the U.S., and sales of next-generation technology. Internationally, the new hardware will be available at the end of next year, but the new software will be introduced by the end of this year. Investigational use-only units may be placed in flagship institutions for clinical work.
Q:Does Swoop have any special use case for patients with neuro implants?
A:Management explained that the low magnetic field strength of Swoop is favorable for patients with magnetic interferences, such as pacemakers or braces. It offers increased safety and better image quality in such cases. They also highlighted favorable FDA labeling for projectile risk, enhancing safety during storage and operation.
Q:Review of Unclear Management Responses
A:Management avoided providing specific metrics or detailed quantification for office placements, deals, or utilization. They also did not provide a clear breakdown of the funnel interest to support the second-half guidance of doubling system placements. Additionally, they used vague language when discussing the balance between accessibility and value for the new technology.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI software
Brett Hale
CEO
Clinicians
FDA clearance
LLC Research
MR technology
MSRP Swoop
NIH
Optive AI
Research Division
Swoop system
adoption scale
advancement
care emergency
channel
clearance manufacturing
deal day
decrease
emergency room
end generation
generation Swoop
generation system
launch generation
phase
position
product launch
quality user
radiologist
reminder
response
role
sale generation
scanner
sequence
system Optive
system deal
system image
traction market
year
HYPR Transcript
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Hyperfine, Inc. (HYPR) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call indicated strong financial performance with an 83% revenue increase and improved gross margins. The strategic plan outlines international expansion and product development, while the Q&A section highlighted positive reception of the Swoop system and no impact from helium shortages. Despite a net loss, reduced R&D expenses and cash burn demonstrate financial discipline. The guidance aligns with growth initiatives, and the company's innovative approach and market potential suggest a positive stock price movement in the near term.
AutoCanada Inc. (ACQ:CA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call revealed significant challenges, including declining revenue and gross profit, operational disruptions, and inventory management issues. The Q&A highlighted ongoing pressures on used vehicle gross profit and the need for a strategic reset. Although there is potential for improvement in the long term, the immediate outlook remains negative due to these persistent challenges and market underperformance.
Hyperfine, Inc. (HYPR) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings report shows strong financial performance with significant revenue and gross profit growth, reduced net loss, and improved cash burn. The optimistic guidance for 2026, strong pipeline, and increased pricing for Model 2 suggest positive future prospects. Despite some management avoidance in addressing specific deal sizes, the overall sentiment is positive, supported by the transition to broader clinical utility and strategic market expansion.
HYPR Slides
HYPR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
